<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781181</url>
  </required_header>
  <id_info>
    <org_study_id>AcibademU</org_study_id>
    <nct_id>NCT02781181</nct_id>
  </id_info>
  <brief_title>Carotid Artery Stenting Without Protection</brief_title>
  <official_title>Carotid Artery Stenting Without Embolic Protection: A Randomized Multicenter Trial (the CASWEP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent randomized Carotid artery stenting (CAS) trial in which carotid protection device
      (CPD)s were used to demonstrate equivalence with carotid endarterectomy (CEA) by achieving
      noninferiority regarding periprocedural risk. However, the clinical efficacy and safety of
      CPDs are still a matter of controversy. It has been argued that the limited reduction
      provided by CPDs may be due to the devices themselves. Probably, they serve as sources for
      emboli during the procedure or removal technique. In general, 30- day adverse outcome for CAS
      with the use of CPDs seems not to be different from the outcome without CPDs.

      Thus, the main goal in this study is to test the hypothesis that CAS without CPD usage is as
      safe as in those patients who undergo CAS with CPD neuroprotection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Carotid Artery Stenting without Embolic Protection (CASWEP) trial is designed in a
      prospective, randomized, multi-center fashion to determine if CAS without CPD is feasible and
      safe in patients with symptomatic or asymptomatic severe carotid stenosis. After the
      exclusion criteria were applied 200 patients were divided as 100 patients in the CAS with CPD
      arm and 100 patients in the CAS without CPD arm. The study population includes patients with
      severe carotid artery stenosis referred to the to the 4 study center hospitals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients experiencing death, stroke, transient ischemic attack (TİA), or Myocardial infarction at 1 month follow up</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Carotid Arteries</condition>
  <arm_group>
    <arm_group_label>CAS with CPD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CAS performed under neuroprotection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAS without CPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAS without neuroprotection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAS with CPD</intervention_name>
    <description>using a neuroprotection device</description>
    <arm_group_label>CAS with CPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAS without CPD</intervention_name>
    <description>No Neuroprotection</description>
    <arm_group_label>CAS without CPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patients with ≥ 50% ipsilateral carotid stenosis by angiography, ≥70% by
             duplex ultrasound, or ≥70% by Computerized tomography (CT) angiography or Magnetic
             Resonance (MR) angiography if the stenosis on ultrasonography was 50% to 69%.

          -  Asymptomatic patients with ≥60% stenosis by angiography, ≥70% by ultrasound, or ≥80%
             by CT angiography or MR angiography if the stenosis on ultrasonography was 50% to 69%.

        Exclusion Criteria:

          -  Previous stroke within 1 month before CAS

          -  Total occlusion,

          -  Visible thrombus at the lesion site

          -  Bleeding diathesis

          -  Cerebral vascular malformation,

          -  Degenerative cerebral diseases

          -  Cerebral tumors

          -  Illness impeding informed consent

          -  Life expectancy&lt;2 years

          -  Previous CEA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SEVKET GORGULU, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sevket Gorgulu, MD</last_name>
    <phone>05052379068</phone>
    <email>sevket5@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adapazari Education and Research Hospital</name>
      <address>
        <city>Adapazari</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERSAN TATLI, MD</last_name>
      <email>&lt;ersantatli@yahoo.com&gt;,</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adiyaman University</name>
      <address>
        <city>Adiyaman</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Musa Çakıcı, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem University</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevket Gorgulu, MD</last_name>
      <email>sevket5@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sevket Gorgulu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Koşuyolu Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SELÇUK PALA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KÜRŞAT TİGEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mehmet Akif Ersoy Education and Training Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>AYDIN YILDIRIM, MD</last_name>
      <email>&lt;aydinyildirim1@hotmail.com&gt;,</email>
    </contact>
    <investigator>
      <last_name>Nevzat Uslu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stenting</keyword>
  <keyword>Protection device</keyword>
  <keyword>EPD usage</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

